Coverage Is the Access Story Now

KFF surveyed 1,117 returning ACA Marketplace enrollees between February 12 and March 2, 2026. Sixty-two percent of the enrollees with a chronic condition have cut or plan to cut spending on food and basic household items to keep their coverage. Not to afford a specialty drug. Not to clear a prior authorization. To keep the insurance card itself. Every affordability argument the industry made this year assumed the patient still held coverage to use. Somebody at a kitchen table already decided otherwise.

KFF published the count on October 14. Individual market enrollment fell from 25.2 million in June 2025 to 20.5 million in June 2026. More than 4.6 million people left in twelve months, an 18 percent decline, and it happened while most of the field argued about list prices and utilization management.

Price explains it. The Peterson-KFF Health System Tracker reviewed 2027 rate filings from 276 insurers across all 50 states and the District of Columbia and found a median proposed increase of 15 percent, with insurers attributing roughly 4 percentage points to the expiration of the enhanced premium tax credits. The sticker matters less than the check. Average premium payments after subsidies rose 58 percent in 2026. A 40-year-old in Indianapolis earning $65,000 paid $316 a month in 2025 and will pay $546 in 2027, a 41 percent increase for the same body and the same plan.

Then the survey data lands on top. Nine percent of people who held Marketplace coverage in 2025 now hold none. Seventeen percent of returning enrollees say they feel not too confident or not at all confident that they can afford premiums for all of 2026. Those people have not dropped yet. They are telling a surveyor exactly when they will.

Congress created the enhanced premium tax credits in the American Rescue Plan Act, extended them through plan year 2025 in the Inflation Reduction Act, and then let them lapse with no replacement. Insurers now price roughly 4 percentage points of the 2027 increase off that one expired budget line. CMS stacked its 2025 Marketplace Integrity and Affordability rule on top of the lapse. UnitedHealthcare of New York attributed 12.7 percent of its requested 2027 rate change to the subsidy expiration and that rule together. Two policy decisions, one bill, and the patient pays it.

Now the uncomfortable half. Pharmaceutical patient assistance and copay programs sit inside commercial organizations that measure enrollment in the program. Count the applications, report the applications, close the year. No advocacy lead at Lilly, Pfizer, Novartis, or any peer owns a metric that would have caught 4.6 million patients walking out of the individual market, because nobody built one. National patient organizations and disease-state groups wrote 2026 policy agendas around drug pricing and prior authorization, and most of them still run no open enrollment navigation for their own members. I have watched enough January agendas get set to know which line item never makes the page. Premium affordability pushed those members out of coverage entirely, and the agenda kept arguing about the price of a drug the member can no longer fill.

He has a newsletter on beehiiv. So do Codie Sanchez, Jay Shetty, David Begnaud, Colin & Samir, and Joanna Stern.

They could publish just about anywhere. They chose beehiiv to build a direct connection with the people who want to hear from them most. And you can do the same, whether you’re world-famous or just at the start of your plan for world domination.

Get started for free.

The organizations that get this right staff enrollment navigation year-round inside the disease community instead of posting a reminder in November, and they measure retained coverage at month twelve rather than sign-ups in week one. They field and publish their own affordability data, and they show the sample size and the method, so payers and state legislators argue against numbers instead of anecdotes. They build the handoff. When a patient assistance program flags somebody about to drop coverage, a navigator calls that week, and the company reports how many of those patients still held insurance a year later. The median organization runs the same three activities, keeps none of those records, and repeats both the November campaign and the budget next year.

Archo has fielded ELAVAY annually since 2015 across more than 20 disease states, asking patient advocacy organizations, professional societies, and community-based organizations how biopharmaceutical companies behave as partners. Companies always grade their own advocacy performance well. The partners they name describe something different. That gap is the finding, and it widens fastest in the work nobody gave an owner. In ELAVAY 2025-2026, 48% of advocacy partners could not say whether patient assistance programs reduce the social barriers to care, a sign the outcome data rarely reaches them. The two most-named programs, Novartis and Pfizer, scored 4.18 and 4.19 on a 7-point scale where 4 is industry average. Eligibility restrictions were the lowest-rated attribute for all four top companies, and 69% of partners asked for easier applications and enrollment support.

Three moves, each one assignable today. Assign one person to map every patient assistance and copay program you run against open enrollment dates in the five states where your patients concentrate, then publish one page that tells patients what to do first. Add one question to your next patient survey: did you change, drop, or lose coverage in the last twelve months, and why. Report that answer with the sample size by the end of Q1. Give one staffer the job of tracking retained coverage at twelve months for every patient your assistance program touched this year, and put that number in the program annual report.

If you want to know whether your advocacy function sits close enough to the decision to matter, take the Advocacy Influence Diagnostic. Free, anonymous, five minutes, and it returns an Advocacy Visibility Index and a Strategic Risk Score. The 2025/2026 ELAVAY Report is available now, and fielding for 2026/2027 opens in October. Or email me directly at [email protected]. Open enrollment opens November 1. The 4.6 million already left.